Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Warm Autoimmune Hemolytic Anemia
NCT04661033Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of isatuximab in warm autoimmune hemolytic anemia (wAIHA) (4 arms), sponsored by Sanofi. Primary endpoints: Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events up to 169 days, Potentially Clinically Significant Abnormality: Hematology up to 169 days and 2 more. Started Sep 2021; status: terminated.
02
Drugs
isatuximab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT04661033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661033.